Ignite Creation Date:
2025-12-24 @ 10:54 PM
Ignite Modification Date:
2026-01-20 @ 9:50 PM
Study NCT ID:
NCT01924169
Status:
TERMINATED
Last Update Posted:
2018-09-20
First Post:
2013-08-13
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Hematologic Disorder | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Hematologic Disorder | View |
| None | Chronic Lymphocytic Leukemia | View |
| None | CLL | View |
| None | Hypogammaglobulinemia | View |
| None | Impaired Response to Vaccinations | View |
| None | Immunoglobulins | View |
| None | Immune system's function | View |
| None | Lenalidomide | View |
| None | CC-5013 | View |
| None | Revlimid | View |
| None | Flu vaccine | View |
| None | TIV | View |
| None | Pneumonia vaccine | View |